ELISA

Developed by the Ragon Institute, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein.

The firm said the contract will help it complete development of the ELISA test and submit for Emergency Use Authorization with the FDA.

The company said its ELISA assay uses the SARS-CoV-2 nucleoprotein as an antigen for the early detection of antibodies against SARS-CoV-2.

The net proceeds will support continued product development, research, product commercialization, working capital, and other general corporate purposes.

The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.

The ELISA-based tests are designed to qualitatively detect three virus-associated antibodies in serum and are being launched immediately.

The assay, called COVID-19 ELISA IgG Antibody Test, detects human IgG antibodies in serum and plasma from individuals suspected of prior infection with SARS-CoV-2.

Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.

The anti-SARS-CoV-2 antibodies for classes IgA and IgG are two of the first antibody detection tests to receive CE making and be made available for SARS-CoV-2 testing.